SIGNA MAGNUS integrates GE HealthCare’s latest deep-learning algorithms. Credit: MMD Creative/Shutterstock.com.

GE HealthCare has introduced SIGNA MAGNUS, a high-performance, head-only magnetic resonance (MR) scanner for exploring advancements in neuroscience.

The system, currently pending 510(k) clearance from the US Food and Drug Administration (FDA), is poised to revolutionise neuroscience research which has been historically limited by the capabilities of conventional whole-body MR systems.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Targeting the expansion of neuroscience research, the scanner is tailored for advanced imaging procedures in neurology, oncology, and psychiatry, aiming to overcome the technological constraints that have previously hindered the study of complex brain disorders.

GE HealthCare MR CEO Kelly Londy said: “With SIGNA MAGNUS, we are not just exploring the possibility of providing the tool; we are setting new benchmarks in medical research and future clinical patient care.

“This innovation underscores our commitment to R&D and our collaborations with academia, pushing the boundaries of what’s possible in MR imaging. The potential impact of SIGNA MAGNUS on patient outcomes and our understanding of the human brain is profound.”

Said to be GE HealthCare’s vision of its most advanced 3.0T MR imaging device, the SIGNA MAGNUS system has superior gradient performance with its HyperG gradient technology, which features 300 mT/m and 750 T/m/s.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

This technology enables the detection of minute details that were previously beyond reach, allowing researchers to explore advanced anatomical, diffusion, and functional techniques.

SIGNA MAGNUS also integrates GE HealthCare’s latest deep-learning algorithms.

In March 2024, research institution Brigham and Women’s Hospital installed the investigational MAGNUS system.

The Brigham team is set to collaborate closely with GE HealthCare in conducting research on high-performance neuro MR.

Last month, GE HealthCare obtained 510(k) clearance from the US FDA for its Portrait vital signs monitor (VSM).

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
HemoSonics has won the 2025 Marketing Award for its impactful promotion of theQuantra Hemostasis System and leadership in blood management education. See how targeted campaigns, thought leadership content, and hands on clinician training are accelerating Quantra’s market traction and shaping the future of hemostasis testing.

Discover the Impact